JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB185633

Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671]

Be the first to review this product! Submit a review

|

(20 Publications)

Rabbit Recombinant Monoclonal AKT1 antibody. Suitable for IP, WB, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse, Rat, Recombinant full length protein - Human samples. Cited in 20 publications.

View Alternative Names

PKB, RAC, AKT1, RAC-alpha serine/threonine-protein kinase, Protein kinase B, Protein kinase B alpha, Proto-oncogene c-Akt, RAC-PK-alpha, PKB alpha, PKBG, AKT3, RAC-gamma serine/threonine-protein kinase, Protein kinase Akt-3, Protein kinase B gamma, RAC-PK-gamma, STK-2, PKB gamma, RAC-beta serine/threonine-protein kinase, Protein kinase Akt-2, Protein kinase B beta, RAC protein kinase beta, PKB beta, RAC-PK-beta, AKT2

10 Images
Flow Cytometry (Intracellular) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Intracellular flow cytometric analysis of 2% paraformaldehyde-fixedA549 (Human lung carcinoma) cells labeling AKT1 + AKT2 + AKT3 with ab185633 at 1/50 dilution (red) compared with a rabbit monoclonal IgG isotype control (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (FITC) at 1/150 dilution was used as the secondary antibody.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Immunohistochemical analysis of paraffin-embedded Human cerebral cortex tissue labeling AKT1 + AKT2 + AKT3 with ab185633 at 1/400 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Nuclear and weak cytoplasmic staining on neurons of the Human cerebral cortex is observed. Counter stained with Hematoxylin.

Negative control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Immunohistochemical analysis of paraffin-embedded Human adenocarcinoma of colon tissue labeling AKT1 + AKT2 + AKT3 with ab185633 at 1/400 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Nuclear and weak cytoplasmic staining on Human adenocarcinoma of colon is observed. Counter stained with Hematoxylin.

Negative control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunoprecipitation - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • IP

Supplier Data

Immunoprecipitation - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

AKT1 + AKT2 + AKT3 was immunoprecipitated from 1mg of A549 (Human lung carcinoma) whole cell extract with ab185633 at 1/50 dilution. Western blot was performed from the immunoprecipitate using ab185633 at 1/1000 dilution. Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG, was used as secondary antibody at 1/1500 dilution.

Lane 1 : A549 whole cell extract 10 μg (Input). Lane 2 : ab185633 IP in A549 whole cell extract. Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab185633 in A549 whole cell extract.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.

All lanes:

Immunoprecipitation - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (ab185633)

Predicted band size: 56 kDa

false

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Immunohistochemical analysis of paraffin-embedded Mouse cerebral cortex tissue labeling AKT1 + AKT2 + AKT3 with ab185633 at 1/400 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Nuclear and weak cytoplasmic staining on neurons of the mouse cerebral cortex is observed. Counter stained with Hematoxylin.

Negative control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Immunohistochemical analysis of paraffin-embedded Rat kidney tissue labeling AKT1 + AKT2 + AKT3 with ab185633 at 1/400 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Nuclear and weak cytoplasmic staining on rat kidney is observed. Counter stained with Hematoxylin.

Negative control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • WB

Supplier Data

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (ab185633) at 1/2000 dilution

Lane 1:

Human fetal brain lysates at 10 µg

Lane 2:

Human fetal kidney lysates at 10 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 56 kDa

Observed band size: 56 kDa

false

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • WB

Supplier Data

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (ab185633) at 1/2000 dilution

All lanes:

A549 (Human lung carcinoma) whole cell lysates at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L),Peroxidase conjugated at 1/1000 dilution

Predicted band size: 141 kDa,56 kDa

Observed band size: 141 kDa,56 kDa

false

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • WB

Supplier Data

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (ab185633) at 1/2000 dilution

Lane 1:

Mouse brain lysates at 10 µg

Lane 2:

Rat brain lysates at 10 µg

Lane 3:

Rat heart lysates at 10 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 56 kDa

Observed band size: 56 kDa

false

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)
  • WB

Supplier Data

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (AB185633)

Blocking/Dilution buffer : 5% NFDM/TBST.

The bottom panel is probed with an anti-His tag antibody.

All lanes:

Western blot - Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] (ab185633) at 1/5000 dilution

Lane 1:

AKT3 recombinant protein fragment (His-Tag®): aa351-479 at 0.01 µg

Lane 2:

AKT2 recombinant protein fragment (His-Tag®): aa282-481 at 0.01 µg

Lane 3:

AKT1 recombinant protein fragment (His-Tag®): aa281-480 at 0.01 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 56 kDa

false

  • Carrier free

    Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671] - BSA and Azide free

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-AKT1 + AKT2 + AKT3 antibody [EPR17671]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR17671

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

Flow Cyt (Intra), WB, IP, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/50", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "<p></p>", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/50", "FlowCytIntra-species-notes": "<p><a href='/en-us/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.</p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/400", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." }, "Mouse": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "<p></p>", "FlowCytIntra-species-checked": "guaranteed", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/400", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." }, "Rat": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "<p></p>", "FlowCytIntra-species-checked": "guaranteed", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/400", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." }, "Recombinant full length protein - Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "<p></p>", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

AKT1 AKT2 and AKT3 also known as Protein Kinase B (PKB) isoforms are serine/threonine-specific protein kinases with critical roles in cellular processes. AKT1 has a molecular weight of about 55.8 kDa AKT2 weighs approximately 56.1 kDa and AKT3 typically has a similar mass. These proteins are expressed in many tissues including brain and heart with AKT1 ubiquitously present AKT2 focused in insulin-responsive tissues and AKT3 mainly in the brain. The molecular weight of AKT plays an important role in their functionality and specificity in tissues.
Biological function summary

AKT proteins regulate cell cycle growing cell survival proliferation and metabolism. They participate as core components of the PI3K/AKT/mTOR signaling pathway forming complexes with other proteins to transmit signals. They bind to phosphoinositide lipids on the cell membrane facilitating their activation and downstream signaling. Through these activities the AKT transporter proteins maintain cellular homeostasis and play a part in stress response.

Pathways

AKT proteins engage in important signaling networks including the PI3K/AKT pathway and mTOR pathway. They work closely with PI3K and mTOR proteins coordinating cellular growth and energy metabolism. In particular the AKT pathway responds to growth factors and insulin influencing glucose uptake and glycolysis regulation through interaction with proteins such as glycogen synthase kinase 3 (GSK3).

Dysregulation of AKT signaling can lead to cancer and diabetes. High AKT activation correlates with various cancers by promoting cell survival and growth. In diabetes impaired AKT2 regulation disrupts glucose uptake affecting insulin response. AKT's relationship with mTOR is significant as it often influences tumor growth and progression in cancerous tissues.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis (PubMed : 11882383, PubMed : 15526160, PubMed : 15861136, PubMed : 21432781, PubMed : 21620960, PubMed : 31204173). This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates (PubMed : 11882383, PubMed : 15526160, PubMed : 21432781, PubMed : 21620960, PubMed : 29343641, PubMed : 31204173). Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported (PubMed : 11882383, PubMed : 15526160, PubMed : 21432781, PubMed : 21620960). AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport (PubMed : 11994271). AKT also regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity (By similarity). Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven (By similarity). AKT also regulates cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase) (PubMed : 11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis (PubMed : 11154276). AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating the mTORC1 signaling pathway, and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1 (PubMed : 12150915, PubMed : 12172553). Also regulates the mTORC1 signaling pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 (PubMed : 31548394, PubMed : 33594058). AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Part of a positive feedback loop of mTORC2 signaling by mediating phosphorylation of MAPKAP1/SIN1, promoting mTORC2 activation (By similarity). AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization (PubMed : 10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319' (PubMed : 10358075). FOXO3 and FOXO4 are phosphorylated on equivalent sites (PubMed : 10358075). AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein) (PubMed : 9829964). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1 (PubMed : 9829964). AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis (By similarity). Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis (By similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth (By similarity). Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor 1 (IGF1) (PubMed : 12176338, PubMed : 12964941). AKT mediates the antiapoptotic effects of IGF1 (By similarity). Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly (PubMed : 19934221). May be involved in the regulation of the placental development (By similarity). Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its : kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3 (PubMed : 17726016). Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its : cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation (PubMed : 20086174). Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation (PubMed : 19592491). Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity (PubMed : 10576742). Phosphorylation of BAD stimulates its pro-apoptotic activity (PubMed : 10926925). Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53 (PubMed : 23431171). Phosphorylates palladin (PALLD), modulating cytoskeletal organization and cell motility (PubMed : 20471940). Phosphorylates prohibitin (PHB), playing an important role in cell metabolism and proliferation (PubMed : 18507042). Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces its release from CDK2 and cytoplasmic relocalization (PubMed : 16982699). These recent findings indicate that the AKT1 isoform has a more specific role in cell motility and proliferation (PubMed : 16139227). Phosphorylates CLK2 thereby controlling cell survival to ionizing radiation (PubMed : 20682768). Phosphorylates PCK1 at 'Ser-90', reducing the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an atypical protein kinase activity using GTP as donor (PubMed : 32322062). Also acts as an activator of TMEM175 potassium channel activity in response to growth factors : forms the lysoK(GF) complex together with TMEM175 and acts by promoting TMEM175 channel activation, independently of its protein kinase activity (PubMed : 32228865). Acts as a regulator of mitochondrial calcium uptake by mediating phosphorylation of MICU1 in the mitochondrial intermembrane space, impairing MICU1 maturation (PubMed : 30504268). Acts as an inhibitor of tRNA methylation by mediating phosphorylation of the N-terminus of METTL1, thereby inhibiting METTL1 methyltransferase activity (PubMed : 15861136). In response to LPAR1 receptor pathway activation, phosphorylates Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which induces WDR44 binding to Rab11, thereby switching Rab11 vesicular function from preciliary trafficking to endocytic recycling (PubMed : 31204173).
See full target information AKT1

Additional targets

RAC-beta serine/threonine-protein kinase,AKT3

Publications (20)

Recent publications for all applications. Explore the full list and refine your search

Biology 14: PubMed40427716

2025

Differential Effects of Rutin and Its Aglycone Quercetin on Cytotoxicity and Chemosensitization of HCT 116 Colon Cancer Cells to Anticancer Drugs 5-Fluorouracil and Doxorubicin.

Applications

Unspecified application

Species

Unspecified reactive species

Iva Suman,Alberta Jezidžić,Dorotea Dobrić,Robert Domitrović

Molecular medicine reports 30: PubMed39370807

2024

MUC1‑ND interacts with TRPV1 to promote corneal epithelial cell proliferation in diabetic dry eye mice by partly activating the AKT signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Haiqiong Li,Yu Zhang,Yuting Chen,Rong Zhu,Weikang Zou,Hui Chen,Jia Hu,Songfu Feng,Yanyan Zhong,Xiaohe Lu

Journal of Cancer 15:5415-5424 PubMed39247610

2024

STAT3 inhibitor Stattic Exhibits the Synergistic Effect with FGFRs Inhibitor Erdafitinib in FGFR1-positive Lung Squamous Cell Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Hongqin Zhong,Ling Wang,Xue Zhu,Shu Li,Xiyue Li,Chen Ding,Ke Wang,Xun Wang

Molecular medicine reports 30: PubMed39219289

2024

inhibits hepatic fibrosis and hepatic stellate cell activation by targeting the PI3K/Akt/mTOR pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Zhiheng Dong,Haibin Guan,Lu Wang,Lijuan Liang,Yifan Zang,Lan Wu,Lidao Bao

World journal of gastrointestinal oncology 16:3241-3255 PubMed39072172

2024

RBM5 suppresses proliferation, metastasis and glycolysis of colorectal cancer cells stabilizing phosphatase and tensin homolog mRNA.

Applications

Unspecified application

Species

Unspecified reactive species

Chu-Xiang Wang,Feng Liu,Yi Wang

Phytotherapy research : PTR 37:195-210 PubMed36097321

2022

Pretreatment with rosavin attenuates PM2.5-induced lung injury in rats through antiferroptosis via PI3K/Akt/Nrf2 signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yilan Wang,Sijing Zhao,Nan Jia,Zherui Shen,Demei Huang,Xiaomin Wang,Yongcan Wu,Caixia Pei,Shihua Shi,Yacong He,Zhenxing Wang

Experimental and therapeutic medicine 23:414 PubMed35601067

2022

Resveratrol protects against atherosclerosis by downregulating the PI3K/AKT/mTOR signaling pathway in atherosclerosis model mice.

Applications

Unspecified application

Species

Unspecified reactive species

Wuguang Ji,Jing Sun,Zonghua Hu,Bo Sun

Frontiers in pharmacology 12:791269 PubMed35342388

2022

Exploring the Pharmacological Mechanisms of Xihuang Pills Against Prostate Cancer Integrating Network Pharmacology and Experimental Validation and .

Applications

Unspecified application

Species

Unspecified reactive species

Yongrong Wu,Xujun You,Qunfang Lin,Wei Xiong,Yinmei Guo,Zhen Huang,Xinjun Dai,Zhengjia Chen,Si Mei,Yan Long,Xuefei Tian,Qing Zhou

Journal of inflammation research 14:4707-4721 PubMed34557015

2021

Astragaloside IV Protects from PM2.5-Induced Lung Injury by Regulating Autophagy via Inhibition of PI3K/Akt/mTOR Signaling in vivo and in vitro.

Applications

Unspecified application

Species

Unspecified reactive species

Caixia Pei,Fei Wang,Demei Huang,Shihua Shi,Xiaomin Wang,Yilan Wang,Shuiqin Li,Yongcan Wu,Zhenxing Wang

Experimental and therapeutic medicine 21:1 PubMed33235610

2020

PM2.5 induces autophagy-mediated cell apoptosis via PI3K/AKT/mTOR signaling pathway in mice bronchial epithelium cells.

Applications

Unspecified application

Species

Unspecified reactive species

Xuemei Han,Yan Zhuang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com